← Leaderboards
Dawn Hershman
Columbia University Health Sciences
$35,977,611
Attributed
$90,815,616
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$114,738,120 · 19
By mechanism
UG1$73,270,599 · 1
P50$29,276,877 · 5
R01$4,985,575 · 3
T32$3,502,944 · 1
P30$948,044 · 2
K12$779,156 · 1
Top collaborators
- Mary Beth Terry14 shared
- Charles D. Blanke13 shared
- Catherine M. Tangen13 shared
- Elizabeth Gross Cohn11 shared
- Erica Phillips11 shared
- Daichi Shimbo11 shared
- Olajide Williams11 shared
- Frank Louis Meyskens5 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Rita Kukafka$6,278,815
- Katherine D Crew$8,241,673
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCommunitiesDesignPoliciesClinical TrialsReportingResearch PersonnelTrainingEnrollmentMalignant Breast NeoplasmBaseCare DeliveryMedicalCancer TherapyQuality Of LifePreventionCancer CareCollaborationsLeadWomanInstitutionPharmaceutical PreparationsRaceCancer Survivor
Grant awards (78)
SWOG NCORP Research Base$6,599,532
UG1 · FY2025 · CA
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)$5,101,431
P50 · FY2025 · MD
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)$787,484
P50 · FY2025 · MD · contact PI
CUIMC Calabresi Clinical Oncology Career Development Program$573,987
K12 · FY2025 · CA · contact PI
Molecular Oncology Training Program$531,167
T32 · FY2025 · CA · contact PI
Cancer Population Science Program$453,661
P30 · FY2025 · CA · contact PI
Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and Reduce Refill Rates after Cancer Surgery$205,625
R34 · FY2025 · DA · contact PI
Admin Core$175,913
P50 · FY2025 · MD
The Impact of HIV on the Tumor Microenviornment and Survival in Colorectal Cancer Patients in South Africa$151,200
K12 · FY2025 · CA · contact PI
SWOG NCORP Research Base$6,795,135
UG1 · FY2024 · CA
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)$4,048,432
P50 · FY2024 · MD
Administrative Core$1,025,313
P50 · FY2024 · MD
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)$1,025,313
P50 · FY2024 · MD
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)$654,071
P50 · FY2024 · MD · contact PI
Molecular Oncology Training Program$483,880
T32 · FY2024 · CA · contact PI
Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and Reduce Refill Rates after Cancer Surgery$246,750
R34 · FY2024 · DA · contact PI
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)$226,727
P50 · FY2024 · MD
Administrative Core$226,727
P50 · FY2024 · MD
Admin Core$214,568
P50 · FY2024 · MD
Cancer Population Science Program$98,875
P30 · FY2024 · CA · contact PI
CUIMC Calabresi Clinical Oncology Career Development Program$53,969
K12 · FY2024 · CA · contact PI
SWOG NCORP Research Base$7,117,835
UG1 · FY2023 · CA
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)$4,049,056
P50 · FY2023 · MD
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)$971,663
P50 · FY2023 · MD
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)$681,609
P50 · FY2023 · MD · contact PI
Molecular Oncology Training Program$516,863
T32 · FY2023 · CA · contact PI
Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and Reduce Refill Rates after Cancer Surgery$287,875
R34 · FY2023 · DA · contact PI
Cancer Disparity Collaborative Supplement: Integrating electronic health record and patient-generated health data for breast cancer and cardiovascular disease risk assessment among diverse multiet...$253,250
UG1 · FY2023 · CA
Admin Core$220,979
P50 · FY2023 · MD
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)$220,979
P50 · FY2023 · MD
Cancer Population Science Program$98,877
P30 · FY2023 · CA · contact PI
SWOG NCORP Research Base$6,808,544
UG1 · FY2022 · CA
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)$4,058,416
P50 · FY2022 · MD
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)$683,321
P50 · FY2022 · MD · contact PI
Molecular Oncology Training Program$479,163
T32 · FY2022 · CA · contact PI
Cancer Population Science Program$98,877
P30 · FY2022 · CA · contact PI
SWOG NCORP Research Base$6,747,401
UG1 · FY2021 · CA
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)$4,220,487
P50 · FY2021 · MD
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)$684,388
P50 · FY2021 · MD · contact PI
Molecular Oncology Training Program$445,219
T32 · FY2021 · CA
Delays in Acquisition of Oral Antineoplastic Agents$227,205
R21 · FY2021 · CA · contact PI
Cancer Population Science Program$98,877
P30 · FY2021 · CA · contact PI
SWOG NCORP Research Base$6,470,524
UG1 · FY2020 · CA
Molecular Oncology Training Program$354,428
T32 · FY2020 · CA
Delays in Acquisition of Oral Antineoplastic Agents$189,338
R21 · FY2020 · CA · contact PI
Cancer Population Science Program$98,877
P30 · FY2020 · CA · contact PI
SWOG NCORP Research Base$5,754,875
UG1 · FY2019 · CA
Molecular Oncology Training Program$284,477
T32 · FY2019 · CA
SWOG NCORP Research Base$4,973,785
UG1 · FY2018 · CA
Molecular Oncology Training Program$247,594
T32 · FY2018 · CA
SWOG NCORP Research Base$4,459,372
UG1 · FY2017 · CA
Molecular Oncology Training Program$160,153
T32 · FY2017 · CA
SWOG NCORP Research Base$3,862,846
UG1 · FY2016 · CA
Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors$318,652
R01 · FY2016 · CA · contact PI
SWOG NCORP Research Base$6,787,504
UG1 · FY2015 · CA
Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients$474,523
R01 · FY2015 · AT · contact PI
Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors$323,796
R01 · FY2015 · CA · contact PI
A randomized trial of topical menthol for chemotherapy induced neuropathy$80,000
R03 · FY2015 · CA · contact PI
SWOG NCORP Research Base$6,639,996
UG1 · FY2014 · CA
Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients$485,276
R01 · FY2014 · AT · contact PI
Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors$314,819
R01 · FY2014 · CA · contact PI
A randomized trial of topical menthol for chemotherapy induced neuropathy$69,600
R03 · FY2014 · CA · contact PI
Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients$508,326
R01 · FY2013 · AT · contact PI
Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors$339,556
R01 · FY2013 · CA · contact PI
Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients$525,161
R01 · FY2012 · AT · contact PI
Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients$121,010
R01 · FY2012 · AT · contact PI
Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients$541,269
R01 · FY2011 · AT · contact PI
Determinants and risks of use and overuse of expensive oncology drugs$252,995
R01 · FY2011 · CA · contact PI
Determinants and risks of use and overuse of expensive oncology drugs$260,820
R01 · FY2010 · CA · contact PI
Determinants and risks of use and overuse of expensive oncology drugs$259,686
R01 · FY2009 · CA · contact PI
Determinants and risks of use and overuse of expensive oncology drugs$259,686
R01 · FY2008 · CA · contact PI
Osteoporosis Prevention in Early Stage Breast Cancer$133,760
K07 · FY2006 · CA · contact PI
Osteoporosis Prevention in Early Stage Breast Cancer$133,761
K07 · FY2005 · CA
Osteoporosis Prevention in Early Stage Breast Cancer$133,761
K07 · FY2004 · CA
Osteoporosis Prevention in Early Stage Breast Cancer$133,761
K07 · FY2003 · CA
Pilot--Ethnic Neutropenia in African Americans and Afro-$0
U54 · FY2003 · CA
Pilot--Ethnic Neutropenia in African-Americans and Afro-Caribbeans$0
U54 · FY2003 · CA
Osteoporosis Prevention in Early Stage Breast Cancer$133,489
K07 · FY2002 · CA